Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

Michael J Davies,1 Katherine W Merton,1 Ujjwala Vijapurkar,2 Dainius A Balis,2 Mehul Desai2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, LLC, Raritan, NJ, USA Objective: Metabolic syndrome refers to a collection of risk factors associated with the d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davies MJ, Merton KW, Vijapurkar U, Balis DA, Desai M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	canagliflozin sodium glucose co-transporter 2 type 2 diabetes metabolic syndrome Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/0fab17479a684dd3b6063eb27630e72e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0fab17479a684dd3b6063eb27630e72e
record_format	dspace
spelling	oai:doaj.org-article:0fab17479a684dd3b6063eb27630e72e2021-12-02T03:50:51ZCanagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome1178-7007https://doaj.org/article/0fab17479a684dd3b6063eb27630e72e2017-01-01T00:00:00Zhttps://www.dovepress.com/canagliflozin-improves-risk-factors-of-metabolic-syndrome-in-patients--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Michael J Davies,1 Katherine W Merton,1 Ujjwala Vijapurkar,2 Dainius A Balis,2 Mehul Desai2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, LLC, Raritan, NJ, USA Objective: Metabolic syndrome refers to a collection of risk factors associated with the development of cardiovascular disease and type 2 diabetes mellitus (T2DM). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight and blood pressure (BP) in a broad range of patients with T2DM. This post hoc analysis assessed the effects of canagliflozin on the components of metabolic syndrome in patients with T2DM and metabolic syndrome.Methods: This analysis was based on data from 2 head-to-head studies of canagliflozin in patients with T2DM on background metformin versus glimepiride (study 1) and background metformin plus sulfonylurea versus sitagliptin 100 mg (study 2). Changes from baseline in glycemic efficacy, anthropometric measures, BP, and lipids were evaluated with canagliflozin versus glimepiride and sitagliptin at week 52 in patients who met ≥2 of the criteria for metabolic syndrome (in addition to T2DM): triglycerides ≥1.7 mmol/L; high-density lipoprotein cholesterol (HDL-C) <1.0 mmol/L (men) or <1.3 mmol/L (women); waist circumference ≥102 cm (non-Asian men), ≥88 cm (non-Asian women), >90 cm (Asian men), or >80 cm (Asian women); diagnosis of hypertension or meeting BP-related criteria (systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg). Safety was assessed based on adverse event reports.Results: In study 1, canagliflozin 100 and 300 mg provided similar and greater HbA1c reductions versus glimepiride, respectively. In study 2, canagliflozin 300 mg provided greater HbA1c lowering versus sitagliptin 100 mg. Canagliflozin also reduced fasting plasma glucose, body weight, body mass index, waist circumference, BP, and triglycerides, and increased HDL-C and low-density lipoprotein cholesterol versus glimepiride and sitagliptin. Canagliflozin was generally well tolerated in each study.Conclusion: Canagliflozin was associated with improvements in all components of metabolic syndrome in patients with T2DM and metabolic syndrome, whereas glimepiride and sitagliptin only improved glycemic components over 52 weeks. Keywords: canagliflozin, sodium glucose co-transporter 2, type 2 diabetes, metabolic syndromeDavies MJMerton KWVijapurkar UBalis DADesai MDove Medical Pressarticlecanagliflozinsodium glucose co-transporter 2type 2 diabetesmetabolic syndromeSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 47-55 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	canagliflozin sodium glucose co-transporter 2 type 2 diabetes metabolic syndrome Specialties of internal medicine RC581-951
spellingShingle	canagliflozin sodium glucose co-transporter 2 type 2 diabetes metabolic syndrome Specialties of internal medicine RC581-951 Davies MJ Merton KW Vijapurkar U Balis DA Desai M Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
description	Michael J Davies,1 Katherine W Merton,1 Ujjwala Vijapurkar,2 Dainius A Balis,2 Mehul Desai2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, LLC, Raritan, NJ, USA Objective: Metabolic syndrome refers to a collection of risk factors associated with the development of cardiovascular disease and type 2 diabetes mellitus (T2DM). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight and blood pressure (BP) in a broad range of patients with T2DM. This post hoc analysis assessed the effects of canagliflozin on the components of metabolic syndrome in patients with T2DM and metabolic syndrome.Methods: This analysis was based on data from 2 head-to-head studies of canagliflozin in patients with T2DM on background metformin versus glimepiride (study 1) and background metformin plus sulfonylurea versus sitagliptin 100 mg (study 2). Changes from baseline in glycemic efficacy, anthropometric measures, BP, and lipids were evaluated with canagliflozin versus glimepiride and sitagliptin at week 52 in patients who met ≥2 of the criteria for metabolic syndrome (in addition to T2DM): triglycerides ≥1.7 mmol/L; high-density lipoprotein cholesterol (HDL-C) <1.0 mmol/L (men) or <1.3 mmol/L (women); waist circumference ≥102 cm (non-Asian men), ≥88 cm (non-Asian women), >90 cm (Asian men), or >80 cm (Asian women); diagnosis of hypertension or meeting BP-related criteria (systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg). Safety was assessed based on adverse event reports.Results: In study 1, canagliflozin 100 and 300 mg provided similar and greater HbA1c reductions versus glimepiride, respectively. In study 2, canagliflozin 300 mg provided greater HbA1c lowering versus sitagliptin 100 mg. Canagliflozin also reduced fasting plasma glucose, body weight, body mass index, waist circumference, BP, and triglycerides, and increased HDL-C and low-density lipoprotein cholesterol versus glimepiride and sitagliptin. Canagliflozin was generally well tolerated in each study.Conclusion: Canagliflozin was associated with improvements in all components of metabolic syndrome in patients with T2DM and metabolic syndrome, whereas glimepiride and sitagliptin only improved glycemic components over 52 weeks. Keywords: canagliflozin, sodium glucose co-transporter 2, type 2 diabetes, metabolic syndrome
format	article
author	Davies MJ Merton KW Vijapurkar U Balis DA Desai M
author_facet	Davies MJ Merton KW Vijapurkar U Balis DA Desai M
author_sort	Davies MJ
title	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
title_short	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
title_full	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
title_fullStr	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
title_full_unstemmed	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
title_sort	canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/0fab17479a684dd3b6063eb27630e72e
work_keys_str_mv	AT daviesmj canagliflozinimprovesriskfactorsofmetabolicsyndromeinpatientswithtype2diabetesmellitusandmetabolicsyndrome AT mertonkw canagliflozinimprovesriskfactorsofmetabolicsyndromeinpatientswithtype2diabetesmellitusandmetabolicsyndrome AT vijapurkaru canagliflozinimprovesriskfactorsofmetabolicsyndromeinpatientswithtype2diabetesmellitusandmetabolicsyndrome AT balisda canagliflozinimprovesriskfactorsofmetabolicsyndromeinpatientswithtype2diabetesmellitusandmetabolicsyndrome AT desaim canagliflozinimprovesriskfactorsofmetabolicsyndromeinpatientswithtype2diabetesmellitusandmetabolicsyndrome
_version_	1718401591533371392

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

Ejemplares similares